Find drug development pipeline and deal Updates information

Lead Product(s): GNOS-PV02, Pembrolizumab, INO-9012

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

Geneos Therapeutics' personalized neoantigen-targeting vaccine, GNOS-PV02, will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).

Lead Product(s): OX401

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Onxeo is building a strong preclinical data set for OX401, optimized for both PARP inhibition and STING response as well as bypass resistance., as homologous recombination deficiency requirements.

Lead Product(s): ALT-702

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

Tumor regression and overall survival in the ALT-702 + anti-CTLA4 group was markedly better than either agent alone.

Lead Product(s): SKY01

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: French Tech Seed

Deal Size: $0.8 million Upfront Cash: Undisclosed

Deal Type: Funding January 20, 2020

Details:

These funds will allow the company to accelerate the development of its flagship drug candidate, before launching a new fundraising round that will address clinical trials.

Lead Product(s): NEO-STC-01

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: BioNTech

Deal Size: $67.0 million Upfront Cash: $67.0 million

Deal Type: Acquisition January 16, 2020

Details:

This acquisition to expand BioNTech's capabilities and strengthens its immunotherapy pipeline.

Lead Product(s): Monoclonal antibody-based therapy

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $10.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 16, 2020

Details:

This additional investment allows AgilVax to continue generating compelling preclinical data with their monoclonal antibody-drug conjugates targeting SLC7A11 (xCT).

Lead Product(s): GEN-001, Avelumab

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Clinical partnership of phase 1/1b combination clinical trial with Genome & Company's GEN-001, and avelumab, Merck KGaA, Darmstadt, Germany and Pfizer Inc.'s anti-PD-L1 antibody in cancer.

Lead Product(s): WP1244

Therapeutic Area: Oncology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

The agreement grants CNS Pharmaceuticals the right to develop and commercialize WP1244, for the potential treatment of primary and metastatic brain cancers.